Giuseppe Bardi graduated at University of Bologna (Italy) in 1998 in Biological Sciences and received the PhD at The Theodor Kocher Institute in Bern (CH) in Cellular and Molecular Immunology in 2001 with a thesis on Chemokine Receptor Signal Transduction.
He worked as postdoc fellow on lymphocyte signaling at The Babraham Institute (Cambridge, UK) and on chemokines/opioids cross-talk signaling in leukocytes at the FELS Institute for Cancer Research and Molecular Biology, Temple University (Philadelphia, PA, USA). From January 2005 he focused on the same topic on neurons as Research Associate in the Dep. of Pharmacology and Physiology at Drexel University (USA). In 2006 he moved back to Italy at Neuroscience Institute CNR (Pisa, Italy) applying his experience in neurobiology and cellular immunology to nanomaterial-induced toxicity and immune responses. He also worked as Contract Professor at the Faculty of Pharmacy, University of Pisa (Italy), teaching recombinant DNA technologies for two semesters.
Giuseppe is a Researcher at the Istituto Italiano di Tecnologia (Genova, Italy) since February 2011, and he has been Scientific Member of the Animal Welfare Body (OPBA, IIT) from 2020 to 2024. His research is focused on interactions of nanomaterials with immune cells. He aims at the development of safe-by-design nanoparticles with specific targeting properties, such as drug carriers and vaccine adjuvants with novel properties.
Giuseppe serves as Associate Editor of Frontiers in Bioengineering - and Biotechnology, Topic Editor for “Nanomaterials” (MDPI), “Vaccines” (MDPI), Editorial Board Member of “Exploration of Immunology” (OEP) and the journal Nanobiomedicine (SAGE publisher). He also actsas reviewer for several scientific journals as well as for the Agenzia Nazionale di Valutazione del Sistema Universitario e della Ricerca (ANVUR) and Polish “National Science Centre” founding agency (Narodowe Centrum Nauki – NCN, Poland).
